MG-K10 for adults and teens with atopic dermatitis
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new drug called MG-K10 for people with atopic dermatitis (also known as eczema) that did not get better with creams or ointments. It aims to see if the drug can help control the condition safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have had atopic dermatitis (eczema) for at least 1 year.
- Your eczema did not get better with prescription creams or ointments, or you cannot use them due to side effects.
- You are willing to use a moisturizer twice a day for the whole study.
- You have not used certain other eczema treatments like biologics or JAK inhibitors recently.
- You do not have active infections like tuberculosis or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
This trial tests a new medication called AK120, given as an injection, to see if it helps teenagers with moderate-to-severe eczema (also called atopic dermatitis) that is not well controlled. It may be a good option for teens who need stronger treatment.
This trial tests a new drug called AK120 for adolescents aged 12 to under 18 with moderate-to-severe atopic dermatitis (eczema). It aims to see if AK120 can improve skin symptoms and quality of life.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This trial tests whether a new medication, galvokimig, can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with creams or ointments. The study will measure how well the drug works, its safety, and how it behaves in your body.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.